Drug intelligence / Profile preview

Shuxinruina

Development stage
Unknown
Lead developer
Jiangsu Nutai Biologics
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Shuxinruina (HT-101) is a recombinant humanized monoclonal antibody targeting Growth Differentiation Factor 15 (GDF15), developed by Jiangsu Hetai Biotechnology and Jiangsu Guiqiong Pharmaceutical. GDF15 is a stress-induced cytokine that plays a pivotal role in the pathogenesis of cancer cachexia by signaling through the GDNF family receptor alpha-like (GFRAL) in the hindbrain to suppress appetite and promote muscle and fat wasting. By neutralizing circulating GDF15, Shuxinruina aims to alleviate anorexia and weight loss, thereby improving the quality of life and potentially the survival of patients with advanced solid tumors. The drug is currently undergoing Phase 1 clinical evaluation in China for the treatment of cancer cachexia and advanced malignancies.

Brand names
Shuxinruina
Other names
GDF15 monoclonal antibodyGDF-15 monoclonal antibodyGDF 15 monoclonal antibody舒心瑞纳
02

Targets

GDF15 (Growth differentiation factor 15)

Beyond the preview

Go deeper on Shuxinruina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuxinruina.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call